Adults (men or women) aged 18 years and older with a diagnosis of primary hypertension for at least 6 months, may qualify to participate. Individuals must currently be treated with at least 2 antihypertensive classes of drug (including a diuretic) at the maximum tolerated doses. Systolic BP between 140 mmHg and 170 mmHg (inclusive) at screening, while on current chronic antihypertensive treatments, is also required.
Participants will receive investigational oral medication (active study drug) or placebo. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 20 weeks and involve about 8 visits to the study centre, plus 1 phone visit.
NCT04277884
Quantum Genomics SA
Brief Summary:
Quantum Genomics SA
Condition or Disease:
Hypertension
Intervention/Treatment:
Drug: Firibastat Drug: PlaceboPhase:
Phase 3
Ages Eligible for Study:
18 Years and older (Adult,Older Adult)
Sexes Eligible for Study:
All
Inclusion Criteria:
Men and women ≥18 years of age at Screening
Diagnosis of primary HTN for at least 6 months prior to Screening
Exclusion Criteria:
Known or suspected secondary HTN (eg, hyperaldosteronism, renovascular HTN, pheochromocytoma, Cushing’s disease).
Automated office SBP >170 mmHg or DBP >110 mmHg at the Screening or Inclusion Visit (Visit 2, Day 1) and confirmed by a second measurement within 30 minutes to 1 hour.
Known hypertensive retinopathy (Keith-Wagener Grade 3 or Grade 4) and/or hypertensive encephalopathy.
Peterborough - Kawartha Cardiology Clinical Trials
Similar Trials
No Similar Trials Found
register now
REGISTER NOW